JP2000507854A - 眼疾患を処置するための装置および方法 - Google Patents
眼疾患を処置するための装置および方法Info
- Publication number
- JP2000507854A JP2000507854A JP9533777A JP53377797A JP2000507854A JP 2000507854 A JP2000507854 A JP 2000507854A JP 9533777 A JP9533777 A JP 9533777A JP 53377797 A JP53377797 A JP 53377797A JP 2000507854 A JP2000507854 A JP 2000507854A
- Authority
- JP
- Japan
- Prior art keywords
- eye
- capsule
- biologically active
- active molecule
- factors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 61
- 208000030533 eye disease Diseases 0.000 title claims description 9
- 208000022873 Ocular disease Diseases 0.000 claims abstract description 14
- 239000002775 capsule Substances 0.000 claims description 93
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 35
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 25
- 230000002137 anti-vascular effect Effects 0.000 claims description 23
- 239000003900 neurotrophic factor Substances 0.000 claims description 20
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 239000003102 growth factor Substances 0.000 claims description 12
- 239000012510 hollow fiber Substances 0.000 claims description 11
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 10
- 238000009792 diffusion process Methods 0.000 claims description 10
- 102000004127 Cytokines Human genes 0.000 claims description 9
- 108090000695 Cytokines Proteins 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 102000006992 Interferon-alpha Human genes 0.000 claims description 7
- 108010047761 Interferon-alpha Proteins 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 7
- 239000005556 hormone Substances 0.000 claims description 7
- 229940088597 hormone Drugs 0.000 claims description 7
- 208000002780 macular degeneration Diseases 0.000 claims description 7
- 239000002858 neurotransmitter agent Substances 0.000 claims description 7
- 108010074338 Lymphokines Proteins 0.000 claims description 6
- 102000008072 Lymphokines Human genes 0.000 claims description 6
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 6
- 210000002159 anterior chamber Anatomy 0.000 claims description 6
- 230000001900 immune effect Effects 0.000 claims description 6
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 5
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 5
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims description 4
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 claims description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 4
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 4
- 108090000467 Interferon-beta Proteins 0.000 claims description 4
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims description 4
- 239000002525 vasculotropin inhibitor Substances 0.000 claims description 4
- -1 IL-1β Proteins 0.000 claims description 3
- 102100026720 Interferon beta Human genes 0.000 claims description 3
- 206010046851 Uveitis Diseases 0.000 claims description 3
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 claims description 2
- 230000000975 bioactive effect Effects 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 5
- 239000012982 microporous membrane Substances 0.000 claims 3
- 230000001413 cellular effect Effects 0.000 claims 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims 1
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 claims 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims 1
- 102000003814 Interleukin-10 Human genes 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 208000032400 Retinal pigmentation Diseases 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 239000000560 biocompatible material Substances 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 107
- 210000001508 eye Anatomy 0.000 description 57
- 108090000623 proteins and genes Proteins 0.000 description 28
- 239000003814 drug Substances 0.000 description 27
- 229940079593 drug Drugs 0.000 description 24
- 101000708766 Homo sapiens Structural maintenance of chromosomes protein 3 Proteins 0.000 description 21
- 239000012528 membrane Substances 0.000 description 17
- 238000011282 treatment Methods 0.000 description 16
- 239000007943 implant Substances 0.000 description 15
- 210000003786 sclera Anatomy 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 239000013604 expression vector Substances 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 229940053128 nerve growth factor Drugs 0.000 description 9
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 7
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 7
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 7
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 7
- 238000001647 drug administration Methods 0.000 description 7
- 238000005538 encapsulation Methods 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 210000001525 retina Anatomy 0.000 description 7
- 208000017442 Retinal disease Diseases 0.000 description 6
- 239000000853 adhesive Substances 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 230000033115 angiogenesis Effects 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 101100352762 Drosophila melanogaster pnut gene Proteins 0.000 description 5
- 108090000099 Neurotrophin-4 Proteins 0.000 description 5
- 230000001070 adhesive effect Effects 0.000 description 5
- 210000000795 conjunctiva Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 229960000485 methotrexate Drugs 0.000 description 5
- 210000001328 optic nerve Anatomy 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 210000001760 tenon capsule Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 210000005166 vasculature Anatomy 0.000 description 5
- 102100028892 Cardiotrophin-1 Human genes 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 102000003683 Neurotrophin-4 Human genes 0.000 description 4
- 239000004695 Polyether sulfone Substances 0.000 description 4
- 206010038848 Retinal detachment Diseases 0.000 description 4
- 206010038923 Retinopathy Diseases 0.000 description 4
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 4
- 108010041776 cardiotrophin 1 Proteins 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 239000003636 conditioned culture medium Substances 0.000 description 4
- 210000004087 cornea Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 108091008695 photoreceptors Proteins 0.000 description 4
- 229920006393 polyether sulfone Polymers 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 3
- 241000289659 Erinaceidae Species 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102100026019 Interleukin-6 Human genes 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 3
- 201000007737 Retinal degeneration Diseases 0.000 description 3
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 108020001096 dihydrofolate reductase Proteins 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000014511 neuron projection development Effects 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 230000000149 penetrating effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000004258 retinal degeneration Effects 0.000 description 3
- 230000004264 retinal detachment Effects 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 210000003556 vascular endothelial cell Anatomy 0.000 description 3
- 210000004127 vitreous body Anatomy 0.000 description 3
- 102400000068 Angiostatin Human genes 0.000 description 2
- 108010079709 Angiostatins Proteins 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 101150074155 DHFR gene Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102400001047 Endostatin Human genes 0.000 description 2
- 108010079505 Endostatins Proteins 0.000 description 2
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 101000927562 Homo sapiens Dopamine beta-hydroxylase Proteins 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 102400000058 Neuregulin-1 Human genes 0.000 description 2
- 108090000556 Neuregulin-1 Proteins 0.000 description 2
- 102000004230 Neurotrophin 3 Human genes 0.000 description 2
- 108090000742 Neurotrophin 3 Proteins 0.000 description 2
- 108010015406 Neurturin Proteins 0.000 description 2
- 102100021584 Neurturin Human genes 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 101001058233 Rattus norvegicus Gamma-enolase Proteins 0.000 description 2
- 208000007135 Retinal Neovascularization Diseases 0.000 description 2
- 206010038910 Retinitis Diseases 0.000 description 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 229960002963 ganciclovir Drugs 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 210000005157 neural retina Anatomy 0.000 description 2
- 210000001178 neural stem cell Anatomy 0.000 description 2
- 239000004090 neuroprotective agent Substances 0.000 description 2
- 230000000508 neurotrophic effect Effects 0.000 description 2
- 229940032018 neurotrophin 3 Drugs 0.000 description 2
- 230000009972 noncorrosive effect Effects 0.000 description 2
- 239000002997 ophthalmic solution Substances 0.000 description 2
- ULSIYEODSMZIPX-UHFFFAOYSA-N phenylethanolamine Chemical compound NCC(O)C1=CC=CC=C1 ULSIYEODSMZIPX-UHFFFAOYSA-N 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920002959 polymer blend Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 210000003994 retinal ganglion cell Anatomy 0.000 description 2
- 210000001116 retinal neuron Anatomy 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 230000001228 trophic effect Effects 0.000 description 2
- 208000026726 vitreous disease Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229940072358 xylocaine Drugs 0.000 description 2
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 208000037859 AIDS-related disorder Diseases 0.000 description 1
- 101800000263 Acidic protein Proteins 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 1
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 102100028728 Bone morphogenetic protein 1 Human genes 0.000 description 1
- 108090000654 Bone morphogenetic protein 1 Proteins 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100385401 Caenorhabditis elegans kin-10 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010055665 Corneal neovascularisation Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 239000009180 Flamin Substances 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108010022901 Heparin Lyase Proteins 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
- 101100404651 Mus musculus Ngf gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 102000014413 Neuregulin Human genes 0.000 description 1
- 108050003475 Neuregulin Proteins 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 102100033857 Neurotrophin-4 Human genes 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000051107 Paraechinus aethiopicus Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 229920012266 Poly(ether sulfone) PES Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 208000016624 Retinal neoplasm Diseases 0.000 description 1
- 208000014139 Retinal vascular disease Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 241000220010 Rhode Species 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 241000244030 Toxocara canis Species 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 108010006886 Vitrogen Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 201000003352 adrenal gland pheochromocytoma Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 201000005667 central retinal vein occlusion Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 201000000159 corneal neovascularization Diseases 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000002788 crimping Methods 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 208000001763 cytomegalovirus retinitis Diseases 0.000 description 1
- 230000004340 degenerative myopia Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 208000011325 dry age related macular degeneration Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 231100000318 excitotoxic Toxicity 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000003619 fibrillary effect Effects 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 210000001542 lens epithelial cell Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 210000004083 nasolacrimal duct Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 229940097998 neurotrophin 4 Drugs 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 201000003841 peripheral retinal degeneration Diseases 0.000 description 1
- 230000005043 peripheral vision Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229950006768 phenylethanolamine Drugs 0.000 description 1
- 230000000649 photocoagulation Effects 0.000 description 1
- 238000013310 pig model Methods 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 229920000131 polyvinylidene Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 208000032253 retinal ischemia Diseases 0.000 description 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 1
- 230000004233 retinal vasculature Effects 0.000 description 1
- 208000004644 retinal vein occlusion Diseases 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 108091008601 sVEGFR Proteins 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000002301 subretinal fluid Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003356 suture material Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000003108 two site enzyme immunoassay Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000006496 vascular abnormality Effects 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 230000004400 visual pathway Effects 0.000 description 1
- 210000000239 visual pathway Anatomy 0.000 description 1
- 229940053728 vitrasert Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
- A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
- A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/620,982 | 1996-03-22 | ||
| US08/620,982 US5904144A (en) | 1996-03-22 | 1996-03-22 | Method for treating ophthalmic diseases |
| PCT/US1997/004701 WO1997034586A2 (en) | 1996-03-22 | 1997-03-24 | Device and method for treating ophthalmic diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006248673A Division JP4740077B2 (ja) | 1996-03-22 | 2006-09-13 | 眼疾患を処置するための装置および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2000507854A true JP2000507854A (ja) | 2000-06-27 |
| JP2000507854A5 JP2000507854A5 (OSRAM) | 2004-12-02 |
Family
ID=24488233
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9533777A Withdrawn JP2000507854A (ja) | 1996-03-22 | 1997-03-24 | 眼疾患を処置するための装置および方法 |
| JP2006248673A Expired - Lifetime JP4740077B2 (ja) | 1996-03-22 | 2006-09-13 | 眼疾患を処置するための装置および方法 |
| JP2010184490A Withdrawn JP2010265314A (ja) | 1996-03-22 | 2010-08-19 | 眼疾患を処置するための装置および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006248673A Expired - Lifetime JP4740077B2 (ja) | 1996-03-22 | 2006-09-13 | 眼疾患を処置するための装置および方法 |
| JP2010184490A Withdrawn JP2010265314A (ja) | 1996-03-22 | 2010-08-19 | 眼疾患を処置するための装置および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5904144A (OSRAM) |
| EP (2) | EP0927024B8 (OSRAM) |
| JP (3) | JP2000507854A (OSRAM) |
| AT (2) | ATE296087T1 (OSRAM) |
| AU (1) | AU716400B2 (OSRAM) |
| CA (1) | CA2264895C (OSRAM) |
| DE (2) | DE69739792D1 (OSRAM) |
| DK (2) | DK0927024T3 (OSRAM) |
| ES (2) | ES2342075T3 (OSRAM) |
| WO (1) | WO1997034586A2 (OSRAM) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003524621A (ja) * | 1999-04-06 | 2003-08-19 | ニューロテック ソシエテ アノニム | カプセル化された細胞ベースの送達のためのプラットホーム細胞株としてのａｒｐｅ−１９ |
| JP2004538056A (ja) * | 2001-07-12 | 2004-12-24 | ペー ローマン クリス | ドライアイの治療のためのインサート |
| JP2007515488A (ja) * | 2003-12-22 | 2007-06-14 | ボーシュ アンド ローム インコーポレイティド | 縫合環を有する薬物送達デバイス |
| JP2007517575A (ja) * | 2004-01-12 | 2007-07-05 | ニューレンズ・リミテッド | 眼球壁碇留固定装置 |
| JP2008515800A (ja) * | 2004-10-04 | 2008-05-15 | セルゲイト， インコーポレイテッド | 眼科疾患の処置剤としてのポリアミン類似化合物 |
| JP2008539996A (ja) * | 2005-05-17 | 2008-11-20 | エヌエスゲーネ・アクティーゼルスカブ | 活性因子によって生物を治療する移植可能な療法システム |
| JP2008543382A (ja) * | 2005-06-10 | 2008-12-04 | シーリート エルエルシー | 神経の維持・再生のための方法およびシステム |
| JP2009522269A (ja) * | 2005-12-30 | 2009-06-11 | ニューロテック ユーエスエー， インコーポレイテッド | 生物活性分子の送達のための微粒子化デバイスおよびその使用方法 |
| JP2010513542A (ja) * | 2006-12-18 | 2010-04-30 | アルコン リサーチ， リミテッド | 眼用薬物送達のためのデバイスおよび方法 |
| JP4881959B2 (ja) * | 2006-01-17 | 2012-02-22 | ニューレンズ・リミテッド | 眼内薬物ディスペンサ |
| JP2022553849A (ja) * | 2019-11-01 | 2022-12-26 | ニューロテック ユーエスエー，インコーポレイティド | 埋め込み可能な検体拡散の機器のためのシステム、装置、機器及び方法 |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6299895B1 (en) * | 1997-03-24 | 2001-10-09 | Neurotech S.A. | Device and method for treating ophthalmic diseases |
| WO1998010785A1 (en) * | 1996-09-13 | 1998-03-19 | Advanced Medicine Research Institute | Ophthalmic compositions of neurotrophic factors, remedies for optic nerve function disorders and method for treating optic nerve function disorders |
| DE19718826A1 (de) * | 1997-05-05 | 1998-11-12 | Marion S Dr Eckmiller | Verwendung biologisch aktiver Wirkstoffe zum Beeinflussen des Extrazellulär-Raumes von Sinneszellen und Verfahren zur Wirkstoff-Administrationssteuerung |
| WO1999013868A1 (en) * | 1997-09-17 | 1999-03-25 | Alcon Laboratories, Inc. | Methods for treating ocular diseases |
| US7282482B2 (en) * | 1998-04-08 | 2007-10-16 | The Regents Of The University Of California | NGF for the prevention of demyelination in the nervous system |
| CA2358296A1 (en) * | 1999-01-05 | 2000-07-13 | Anthony P. Adamis | Targeted transscleral controlled release drug delivery to the retina and choroid |
| US20070071734A1 (en) * | 1999-04-06 | 2007-03-29 | Weng Tao | ARPE-19 as platform cell line for encapsulated cell-based delivery |
| JP2003510015A (ja) * | 1999-05-07 | 2003-03-18 | アメリカ合衆国 | 抗血管形成性化合物を用いる腫瘍の処置方法 |
| JP4837861B2 (ja) * | 1999-10-21 | 2011-12-14 | アルコン，インコーポレイティド | ドラッグデリバリ製剤 |
| US7943162B2 (en) * | 1999-10-21 | 2011-05-17 | Alcon, Inc. | Drug delivery device |
| ES2240180T3 (es) | 1999-10-21 | 2005-10-16 | Alcon Inc. | Administracion sub-tenon de medicamentos. |
| US6416777B1 (en) * | 1999-10-21 | 2002-07-09 | Alcon Universal Ltd. | Ophthalmic drug delivery device |
| US6267954B1 (en) * | 1999-11-24 | 2001-07-31 | Universite De Paris V Rene-Descartes | Intraocular transplantation of encapsulated cells |
| JP2003522160A (ja) * | 2000-02-11 | 2003-07-22 | ジェンベク、インコーポレイティッド | 眼関連疾患の治療のための遺伝子治療 |
| ES2312456T3 (es) * | 2000-08-30 | 2009-03-01 | Johns Hopkins University | Dispositivos para suministro intraocular de farmacos. |
| US6697668B2 (en) * | 2001-01-25 | 2004-02-24 | Iomed, Inc. | Ocular iontophoretic device and method for using the same |
| US6546284B2 (en) * | 2001-01-25 | 2003-04-08 | Iomed, Inc. | Fluid retention assembly for an iontophoretic delivery device and associated method for preparing the same |
| US7181287B2 (en) * | 2001-02-13 | 2007-02-20 | Second Sight Medical Products, Inc. | Implantable drug delivery device |
| US6875165B2 (en) | 2001-02-22 | 2005-04-05 | Retinalabs, Inc. | Method of radiation delivery to the eye |
| JP2004536631A (ja) | 2001-05-03 | 2004-12-09 | マサチューセッツ・アイ・アンド・イア・インファーマリー | 移植可能な薬物送達デバイスおよびその使用 |
| ATE506929T1 (de) | 2001-06-12 | 2011-05-15 | Univ Johns Hopkins Med | Reservoirvorrichtung für die intraokulare arzneimittelabgabe |
| US7031776B2 (en) | 2001-06-29 | 2006-04-18 | Optobionics | Methods for improving damaged retinal cell function |
| US20050033202A1 (en) * | 2001-06-29 | 2005-02-10 | Chow Alan Y. | Mechanically activated objects for treatment of degenerative retinal disease |
| WO2003009774A2 (en) | 2001-07-23 | 2003-02-06 | Alcon, Inc. | Ophthalmic drug delivery device |
| PL204645B1 (pl) * | 2001-07-23 | 2010-01-29 | Alcon | Okulistyczne urządzenie do podawania leków |
| PL207175B1 (pl) * | 2001-08-01 | 2010-11-30 | Merck Patent Gmbh | Zastosowanie inhibitorów integryny do wytwarzania kompozycji farmaceutycznych do zapobiegania i/lub terapii chorób oczu |
| AU2003217531A1 (en) * | 2002-05-02 | 2003-11-17 | Massachusetts Eye And Ear Infirmary | Ocular drug delivery systems and use thereof |
| WO2004028477A2 (en) * | 2002-09-29 | 2004-04-08 | Surmodics, Inc. | Methods for treatment and/or prevention of retinal disease |
| US20060167435A1 (en) * | 2003-02-18 | 2006-07-27 | Adamis Anthony P | Transscleral drug delivery device and related methods |
| US8246974B2 (en) * | 2003-05-02 | 2012-08-21 | Surmodics, Inc. | Medical devices and methods for producing the same |
| WO2004098565A2 (en) * | 2003-05-02 | 2004-11-18 | Surmodics, Inc. | Implantable controlled release bioactive agent delivery device |
| US7601518B2 (en) | 2003-06-10 | 2009-10-13 | Nsgene A/S | Secretion of neublastin |
| AU2004258857A1 (en) * | 2003-07-10 | 2005-02-03 | Alcon, Inc. | Ophthalmic drug delivery device |
| CN1882338A (zh) * | 2003-09-18 | 2006-12-20 | 马库赛特公司 | 经巩膜递送 |
| AU2004283053A1 (en) | 2003-10-20 | 2005-05-06 | Nsgene A/S | In vivo gene therapy of Parkinson's Disease |
| EP1720608B1 (en) * | 2004-02-12 | 2010-11-17 | NeoVista, Inc. | Apparatus for intraocular brachytherapy |
| US7563222B2 (en) * | 2004-02-12 | 2009-07-21 | Neovista, Inc. | Methods and apparatus for intraocular brachytherapy |
| ATE430763T1 (de) | 2004-03-30 | 2009-05-15 | Nsgene As | Therapeutische verwendung des wachstumsfaktors nsg33 |
| WO2006002366A2 (en) * | 2004-06-24 | 2006-01-05 | Surmodics, Inc. | Biodegradable ocular devices, methods and systems |
| WO2006014484A2 (en) * | 2004-07-02 | 2006-02-09 | Surmodics, Inc. | Methods and devices for the treatment of ocular conditions |
| US20090136552A1 (en) * | 2004-07-30 | 2009-05-28 | Mette Gronborg | Growth factors nsg28, nsg30, and nsg32 |
| US20060034891A1 (en) * | 2004-08-12 | 2006-02-16 | Laurie Lawin | Biodegradable controlled release bioactive agent delivery device |
| US8246569B1 (en) | 2004-08-17 | 2012-08-21 | California Institute Of Technology | Implantable intraocular pressure drain |
| WO2006086750A1 (en) * | 2005-02-09 | 2006-08-17 | Macusight, Inc. | Liquid formulations for treatment of diseases or conditions |
| US8663639B2 (en) * | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
| TW200640443A (en) * | 2005-02-23 | 2006-12-01 | Alcon Inc | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors |
| US20060233858A1 (en) * | 2005-03-08 | 2006-10-19 | Allergan, Inc. | Systems and methods providing targeted intraocular drug delivery |
| US20070077270A1 (en) * | 2005-03-28 | 2007-04-05 | Clemson University | Delivery devices and methods for long-term, targeted delivery of therapeutic agents to the eye and ear |
| WO2006102902A1 (en) | 2005-04-01 | 2006-10-05 | Nsgene A/S | A human immortalised neural precursor cell line |
| WO2006110487A1 (en) * | 2005-04-08 | 2006-10-19 | Surmodics, Inc. | Sustained release implants for subretinal delivery |
| US20060258994A1 (en) * | 2005-05-12 | 2006-11-16 | Avery Robert L | Implantable delivery device for administering pharmacological agents to an internal portion of a body |
| EP2374451A3 (en) | 2005-07-27 | 2012-01-25 | University of Florida Research Foundation, Inc. | Histone deacetylase inhibitors (HDAC) that correct protein misfolding and uses thereof |
| EP1951372A4 (en) | 2005-11-15 | 2011-06-22 | Neovista Inc | METHOD AND DEVICE FOR INTRA-ECULAR BRACHYTHERAPY |
| US20080293691A1 (en) | 2005-11-29 | 2008-11-27 | Smithkline Beecham Corporation | Treatment Method |
| CA2635797C (en) | 2006-02-09 | 2015-03-31 | Macusight, Inc. | Stable formulations, and methods of their preparation and use |
| ES2493921T3 (es) * | 2006-03-14 | 2014-09-12 | University Of Southern California | Dispositivo MEMS para la administración de agentes terapéuticos |
| WO2007112052A2 (en) | 2006-03-23 | 2007-10-04 | Macusight, Inc. | Formulations and methods for vascular permeability-related diseases or conditions |
| US20080265343A1 (en) * | 2007-04-26 | 2008-10-30 | International Business Machines Corporation | Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof |
| US9308124B2 (en) * | 2007-12-20 | 2016-04-12 | University Of Southern California | Apparatus and methods for delivering therapeutic agents |
| EP2240220B1 (en) | 2008-01-03 | 2016-04-13 | University Of Southern California | Implantable drug-delivery devices, and apparatus for refilling the devices |
| US9199035B2 (en) * | 2008-05-08 | 2015-12-01 | Minipumps, Llc. | Drug-delivery pumps with dynamic, adaptive control |
| US9162024B2 (en) | 2008-05-08 | 2015-10-20 | Minipumps, Llc | Drug-delivery pumps and methods of manufacture |
| WO2009137777A2 (en) | 2008-05-08 | 2009-11-12 | Replenish Pumps, Llc | Implantable drug-delivery devices, and apparatus and methods for filling the devices |
| US9333297B2 (en) | 2008-05-08 | 2016-05-10 | Minipumps, Llc | Drug-delivery pump with intelligent control |
| EP2898911A1 (en) * | 2008-05-08 | 2015-07-29 | MiniPumps, LLC | Implantable pumps and cannulas therefor |
| AU2009256236A1 (en) | 2008-06-04 | 2009-12-10 | Neovista, Inc. | Handheld radiation delivery system for advancing a radiation source wire |
| US20120021039A1 (en) | 2009-01-23 | 2012-01-26 | Nsgene A/S | Expression of neuropeptides in mammalian cells |
| CN102361971A (zh) | 2009-01-23 | 2012-02-22 | Ns基因公司 | 改善的细胞系以及在胶囊化细胞生物递送中的用途 |
| US8372036B2 (en) * | 2009-05-06 | 2013-02-12 | Alcon Research, Ltd. | Multi-layer heat assembly for a drug delivery device |
| IN2012DN00352A (OSRAM) | 2009-06-16 | 2015-08-21 | Bikam Pharmaceuticals Inc | |
| US20120232102A1 (en) | 2009-09-30 | 2012-09-13 | Chun-Fang Xu | Methods Of Administration And Treatment |
| US8177747B2 (en) * | 2009-12-22 | 2012-05-15 | Alcon Research, Ltd. | Method and apparatus for drug delivery |
| JP5852655B2 (ja) | 2010-09-27 | 2016-02-03 | エヌエスジーン・アクティーゼルスカブＮｓＧｅｎｅ Ａ／Ｓ | 支持・放射状拡散スカフォールディングを備える埋込み型細胞デバイス |
| EP2621512B1 (en) | 2010-10-01 | 2016-04-06 | NsGene A/S | Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain |
| US9919099B2 (en) | 2011-03-14 | 2018-03-20 | Minipumps, Llc | Implantable drug pumps and refill devices therefor |
| US10286146B2 (en) | 2011-03-14 | 2019-05-14 | Minipumps, Llc | Implantable drug pumps and refill devices therefor |
| US9603997B2 (en) | 2011-03-14 | 2017-03-28 | Minipumps, Llc | Implantable drug pumps and refill devices therefor |
| US9133082B2 (en) | 2011-06-14 | 2015-09-15 | Bikam Pharmaceuticals, Inc. | Opsin-binding ligands, compositions and methods of use |
| CA2846511C (en) | 2011-09-05 | 2021-07-13 | Nsgene A/S | Treatment of allodynia, hyperalgsia, spontaneous pain, and phantom pain with cometin |
| US9499464B2 (en) | 2011-10-19 | 2016-11-22 | Bikam Pharmaceuticals, Inc. | Opsin-binding ligands, compositions and methods of use |
| EP2785346A4 (en) | 2011-11-30 | 2015-04-29 | Bikam Pharmaceuticals Inc | OPSINBINDING LIGANDS, COMPOSITIONS THEREOF, AND METHOD OF USE THEREOF |
| CA2862746A1 (en) | 2011-12-01 | 2013-06-06 | Bikam Pharmaceuticals, Inc. | Opsin-binding ligands, compositions and methods of use |
| RU2494711C1 (ru) * | 2012-05-18 | 2013-10-10 | Федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения и социального развития Российской Федерации | Способ хирургического лечения прогрессирующей и осложненной миопии |
| MX388762B (es) | 2012-06-01 | 2025-03-20 | Surmodics Inc | Aparato y método para recubrir catéteres con globo. |
| US9827401B2 (en) | 2012-06-01 | 2017-11-28 | Surmodics, Inc. | Apparatus and methods for coating medical devices |
| US11090468B2 (en) | 2012-10-25 | 2021-08-17 | Surmodics, Inc. | Apparatus and methods for coating medical devices |
| US9526654B2 (en) | 2013-03-28 | 2016-12-27 | Forsight Vision4, Inc. | Ophthalmic implant for delivering therapeutic substances |
| US9925219B2 (en) | 2013-09-11 | 2018-03-27 | Neurotech Usa, Inc. | Encapsulated cell therapy cartridge |
| AU2015346450B2 (en) | 2014-11-10 | 2020-01-30 | Forsight Vision4, Inc. | Expandable drug delivery devices and method of use |
| EP3439591B1 (en) | 2016-04-05 | 2020-09-23 | ForSight Vision4, Inc. | Implantable ocular drug delivery devices |
| WO2020112816A1 (en) | 2018-11-29 | 2020-06-04 | Surmodics, Inc. | Apparatus and methods for coating medical devices |
| US11819590B2 (en) | 2019-05-13 | 2023-11-21 | Surmodics, Inc. | Apparatus and methods for coating medical devices |
| CA3169482A1 (en) | 2020-02-26 | 2021-09-02 | Krzysztof Palczewski | Compositions and methods for treating misfolded protein ocular disorders |
| US12496612B2 (en) | 2021-01-08 | 2025-12-16 | Surmodics, Inc. | Coating application system and methods for coating rotatable medical devices |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5116798A (ja) * | 1974-08-01 | 1976-02-10 | Mihairoichi Kurasunofu Mihairu | Jinkosuishotai |
| US5266562A (en) * | 1987-11-19 | 1993-11-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Anti-inflammatory agents |
| US5521215A (en) * | 1989-11-07 | 1996-05-28 | Ramot University Authority For Applied Research And Industrial Development Ltd. | NMDA-blocking pharmaceuticals |
| US5378475A (en) * | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
| US5382514A (en) * | 1992-03-31 | 1995-01-17 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | In vivo angiogenesis assay |
| US5178635A (en) * | 1992-05-04 | 1993-01-12 | Allergan, Inc. | Method for determining amount of medication in an implantable device |
| US5279298A (en) * | 1992-11-20 | 1994-01-18 | The Johns Hopkins University | Method and apparatus to identify and treat neovascular membranes in the eye |
| US5443505A (en) * | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| US5550050A (en) * | 1994-04-15 | 1996-08-27 | Cytotherapeutics, Inc. | Method for implanting encapsulated cells in a host |
| US5466233A (en) * | 1994-04-25 | 1995-11-14 | Escalon Ophthalmics, Inc. | Tack for intraocular drug delivery and method for inserting and removing same |
| US5472436A (en) * | 1994-07-26 | 1995-12-05 | Fremstad; Daria A. | Ocular appliance for delivering medication |
-
1996
- 1996-03-22 US US08/620,982 patent/US5904144A/en not_active Expired - Lifetime
-
1997
- 1997-03-24 DK DK97916936T patent/DK0927024T3/da active
- 1997-03-24 CA CA002264895A patent/CA2264895C/en not_active Expired - Fee Related
- 1997-03-24 WO PCT/US1997/004701 patent/WO1997034586A2/en not_active Ceased
- 1997-03-24 DK DK05010733.3T patent/DK1574209T3/da active
- 1997-03-24 AT AT97916936T patent/ATE296087T1/de active
- 1997-03-24 ES ES05010733T patent/ES2342075T3/es not_active Expired - Lifetime
- 1997-03-24 ES ES97916936T patent/ES2242223T3/es not_active Expired - Lifetime
- 1997-03-24 DE DE69739792T patent/DE69739792D1/de not_active Expired - Lifetime
- 1997-03-24 JP JP9533777A patent/JP2000507854A/ja not_active Withdrawn
- 1997-03-24 DE DE69733357T patent/DE69733357T2/de not_active Expired - Lifetime
- 1997-03-24 EP EP97916936A patent/EP0927024B8/en not_active Expired - Lifetime
- 1997-03-24 AT AT05010733T patent/ATE459335T1/de not_active IP Right Cessation
- 1997-03-24 EP EP05010733A patent/EP1574209B1/en not_active Expired - Lifetime
- 1997-03-24 AU AU25419/97A patent/AU716400B2/en not_active Ceased
-
2006
- 2006-09-13 JP JP2006248673A patent/JP4740077B2/ja not_active Expired - Lifetime
-
2010
- 2010-08-19 JP JP2010184490A patent/JP2010265314A/ja not_active Withdrawn
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003524621A (ja) * | 1999-04-06 | 2003-08-19 | ニューロテック ソシエテ アノニム | カプセル化された細胞ベースの送達のためのプラットホーム細胞株としてのａｒｐｅ−１９ |
| JP2004538056A (ja) * | 2001-07-12 | 2004-12-24 | ペー ローマン クリス | ドライアイの治療のためのインサート |
| JP2007515488A (ja) * | 2003-12-22 | 2007-06-14 | ボーシュ アンド ローム インコーポレイティド | 縫合環を有する薬物送達デバイス |
| JP2007517575A (ja) * | 2004-01-12 | 2007-07-05 | ニューレンズ・リミテッド | 眼球壁碇留固定装置 |
| JP2008515800A (ja) * | 2004-10-04 | 2008-05-15 | セルゲイト， インコーポレイテッド | 眼科疾患の処置剤としてのポリアミン類似化合物 |
| US9364427B2 (en) | 2005-05-17 | 2016-06-14 | Nsgene A/S | Implantable therapy system for treating a living being with an active factor |
| JP2008539996A (ja) * | 2005-05-17 | 2008-11-20 | エヌエスゲーネ・アクティーゼルスカブ | 活性因子によって生物を治療する移植可能な療法システム |
| JP2008543382A (ja) * | 2005-06-10 | 2008-12-04 | シーリート エルエルシー | 神経の維持・再生のための方法およびシステム |
| KR101326611B1 (ko) | 2005-06-10 | 2013-11-08 | 디 인벤션 사이언스 펀드 원, 엘엘씨 | 신경의 유지 및 재생을 위한 방법 및 시스템 |
| JP2009522269A (ja) * | 2005-12-30 | 2009-06-11 | ニューロテック ユーエスエー， インコーポレイテッド | 生物活性分子の送達のための微粒子化デバイスおよびその使用方法 |
| JP4881959B2 (ja) * | 2006-01-17 | 2012-02-22 | ニューレンズ・リミテッド | 眼内薬物ディスペンサ |
| JP2010513542A (ja) * | 2006-12-18 | 2010-04-30 | アルコン リサーチ， リミテッド | 眼用薬物送達のためのデバイスおよび方法 |
| JP2022553849A (ja) * | 2019-11-01 | 2022-12-26 | ニューロテック ユーエスエー，インコーポレイティド | 埋め込み可能な検体拡散の機器のためのシステム、装置、機器及び方法 |
| JP7783807B2 (ja) | 2019-11-01 | 2025-12-10 | ニューロテック ユーエスエー，インコーポレイティド | 埋め込み可能な検体拡散の機器のためのシステム、装置、機器及び方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| DE69739792D1 (de) | 2010-04-15 |
| DK1574209T3 (da) | 2010-05-31 |
| EP1574209A1 (en) | 2005-09-14 |
| JP2006342185A (ja) | 2006-12-21 |
| AU2541997A (en) | 1997-10-10 |
| CA2264895C (en) | 2008-05-27 |
| EP0927024A2 (en) | 1999-07-07 |
| ATE459335T1 (de) | 2010-03-15 |
| EP1574209B1 (en) | 2010-03-03 |
| WO1997034586A2 (en) | 1997-09-25 |
| DE69733357T2 (de) | 2006-02-02 |
| DE69733357D1 (de) | 2005-06-30 |
| EP0927024B8 (en) | 2005-08-31 |
| US5904144A (en) | 1999-05-18 |
| AU716400B2 (en) | 2000-02-24 |
| ATE296087T1 (de) | 2005-06-15 |
| ES2342075T3 (es) | 2010-07-01 |
| EP0927024B1 (en) | 2005-05-25 |
| JP4740077B2 (ja) | 2011-08-03 |
| DK0927024T3 (da) | 2005-08-29 |
| JP2010265314A (ja) | 2010-11-25 |
| WO1997034586A3 (en) | 1997-10-23 |
| CA2264895A1 (en) | 1997-09-25 |
| ES2242223T3 (es) | 2005-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4740077B2 (ja) | 眼疾患を処置するための装置および方法 | |
| US6299895B1 (en) | Device and method for treating ophthalmic diseases | |
| JP4954374B2 (ja) | カプセル化された細胞ベースの送達のためのプラットホーム細胞株としてのａｒｐｅ−１９ | |
| JP4524230B2 (ja) | 遺伝的に改変された細胞を含む生体適合性免疫隔離カプセル | |
| US9265814B2 (en) | Micronized device for the delivery of biologically active molecules and methods of use thereof | |
| US20160120695A1 (en) | Use of pedf in an encapsulated cell-based delivery system | |
| US6267954B1 (en) | Intraocular transplantation of encapsulated cells | |
| US20240335562A1 (en) | Sustainable ocular cell-mediated intraocular delivery of cellular therapeutics for treatment of ocular diseases or disorders | |
| AU708536B2 (en) | System and method for delivery of cytokines using encapsulated cytokine-secreting cells | |
| CN101351230A (zh) | 用于投递gdnf的可植入式生物相容性免疫绝缘性媒介物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040305 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040305 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060314 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060607 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060724 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20060913 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20060911 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070206 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070531 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20070614 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20070802 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20080423 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090708 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090716 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091225 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20100826 |